← Back to Search

Secukinumab 1 for Hidradenitis Suppurativa (SUNRISE Trial)

Phase 3
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

SUNRISE Trial Summary

This study is evaluating whether a medication may help treat hidradenitis suppurativa.

Eligible Conditions
  • Hidradenitis Suppurativa

SUNRISE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
Secondary outcome measures
Percentage Change From Baseline in AN Count
Percentage of Participants Achieving NRS30
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares

SUNRISE Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: Secukinumab 1Active Control1 Intervention
Secukinumab 300mg every 2 weeks
Group II: Secukinumab 2Active Control1 Intervention
Secukinumab 300mg every 4 weeks
Group III: Placebo 1Placebo Group1 Intervention
Placebo group to secukinumab 300mg every 2 weeks
Group IV: Placebo 2Placebo Group1 Intervention
Placebo group to secukinumab 300mg every 4 weeks

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,855 Previous Clinical Trials
4,196,874 Total Patients Enrolled
6 Trials studying Hidradenitis Suppurativa
2,159 Patients Enrolled for Hidradenitis Suppurativa
Study Lead Study DirectorStudy DirectorNovartis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
2019. "Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03713632.
~90 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top